Novo Nordisk's plan to gain ground in the GLP-1 space is slowly taking shape.
Stocktwits on MSN
Novo Nordisk to launch Ozempic pills following flat growth in diabetes segment in 2025
A Novo executive noted that many customers are unaware that the company already makes oral semaglutide for type 2 diabetes ...
Novo Nordisk vowed to take legal action against telehealth company Hims & Hers for selling a knockoff of its weight loss pill ...
Semaglutide is the active ingredient in Ozempic and Wegovy. It’s a synthetic form of GLP-1, a hormone that regulates our ...
Hims & Hers unlawfully mass markets unapproved versions of Novo Nordisk’s FDA-approved semaglutide medicines, deceiving ...
Novo Nordisk threatens legal action against Hims & Hers for "duping" public with cheap compounds of its popular weight-loss ...
Novo Nordisk (NVO) stock falls after issuing weak outlook for 2026 due to pricing pressure and competition. Q4 earnings beat.
Novo Nordisk today announced the launch of a new consumer campaign for Ozempic (R) (semaglutide) injection 0.5 mg, 1 mg, and 2 mg, reinventing how traditional pharma advertising is being done. The ...
Novo Nordisk is considering additional regulatory filings for CagriSema – already submitted in the US for obesity – after the drug outperformed Ozempic in a head-to-head diabetes study.
The once high-flying Danish drugmaker has struggled to fend off rivals in the weight-loss industry, especially Eli Lilly, ...
The new Ozempic name is intended to help patients and healthcare professionals more easily recognize the available ...
Novo Nordisk brought in Justin Long and John Hodgman, who had been in the Apple "Get A Mac" ads from 20 years ago, to star in the new "Only One Ozempic" commercials.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results